Enhanced Binding Analysis Service

Follow-up Data for Novel Binding Interactions

Home » Membrane Proteome Array » Enhanced Binding Analysis for Novel Interactions

Experimental Design | Project Deliverables | Request Information

When your specificity screen returns an off-target binding interaction, Enhanced Binding Analysis is the next step

Enhanced Binding Analysis is a follow-on service to our Membrane Proteome Array (MPA) screening service. If your MPA screen returns an off-target binding event, this service provides deeper statistical, biological, and molecular insights for those off targets.

These data comply with FDA guidance that “nonclinical evaluation of the antigen recognition domain should include assessment of the specificity and affinity/avidity for the target antigen/cells to evaluate the potential for on-target/off-tumor and off-target toxicities.” (FDA, 2024, Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products)

With this service package, we can help you investigate:

The significance of off-target binding relative to your target; differentiating weak binding interactions and low off-target expression
The relative binding strength (affinity/avidity) of an off-target protein vs. your target protein, including EC50 and maximum binding (Bmax) calculations
Biological insights into sub-cellular and human tissue distribution of the off-target protein to determine if the off-target is accessible to your drug

Enhanced Binding Analysis Service Experimental Design

Test antibody run in triplicate for the highest confidence, even with weak off-targets
8-point, 2-fold titration with 4 replicates at each concentration for statistical analysis
Additional transfection, binding, isotype, and expression controls for comparison
Immunofluorescent imaging, permeabilization controls, and bioinformatic analysis for sub-cellular and tissue localization to determine if the off-target is accessible to your drug